Brief: Abionyx Pharma Receives FDA Orphan Drug Designation (Odd) For Cer-001 For The Treatment Of Lcat Deficiency Presenting As Kidney Dysfunction And/Or Ophthalmologic Disease

Abionyx Pharma SA

29/03/2022 19:43

March 29 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * ABIONYX PHARMA RECEIVES FDA ORPHAN DRUG DESIGNATION (ODD)
FOR
CER-001 FOR THE TREATMENT OF LCAT DEFICIENCY PRESENTING AS
KIDNEY DYSFUNCTION AND/OR OPHTHALMOLOGIC DISEASE

Source text for Eikon:  urn:newsml:reuters.com:*:nBw3qyBqwa
Further company coverage:  ABNX.PA 

 ((Reuters.Briefs@thomsonreuters.com;;))